Cydectin LA
Active substance
ATC code
Species
Sheep above 15kg bodyweight.
Indications
Treatment and prevention of mixed infections of gastro-intestinal nematodes, respiratory nematodes and certain arthropod parasites in sheep.
Moxidectin is indicated for treatment of infections caused by moxidectin sensitive strains of:
- Gastro-intestinal nematodes:
. Haemonchus contortus (adults and L3)
. Ostertagia (Teladorsagia) circumcincta (adults and L3, including inhibited larvae)
. Trichostrongylus axei (adults)
. Trichostrongylus colubriformis (adults and L3)
. Nematodirus spathiger (adults)
. Cooperia curticei (macmasteri) (adults)
. Cooperia punctata (adults)
. Oesophagostomum columbianum (L3)
. Chabertia ovina (adults)
- Respiratory tract nematodes
Dictyocaulus filaria (adults)
- Larvae of Diptera
. Oestrus ovis: L1, L2, L3
- Mange mites
. Psoroptes ovis
Trials have shown that moxidectin is effective against certain strains of Haemonchus contortus, Teladorsagia circumcincta and Trichostrongylus spp. resistant to benzimidazoles.
The product has a persistent action and protects sheep against infection or reinfection with the following parasites for the period indicated:
| Species | Days |
| Ostertagia (Teladorsagia) circumcincta | 97 |
| Haemonchus contortus | 111 |
| Trichostrongylus colubriformis |
44 |
| Psoroptes ovis |
60 |
Persistent efficacy periods have not been established for parasite species other than those included in the list above. Therefore, re-infection of animals on pasture contaminated by parasites other than these remains possible before the 44 day minimum persistency period demonstrated for specific species.
Dose to be administered and administration route
Dosage is 0.5 ml/10 kg bodyweight to give 1 mg moxidectin/ kg bodyweight. The 50ml vial stoppers must not be broached more than 10 times. Use automatic syringe equipment for the 200 ml and 500ml vials.
To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked. If animals are to be treated collectively rather than individually, they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- or overdosing.
The injection should be administered as a single subcutaneous injection at the base of the ear using an 18 gauge, 25 mm hypodermic needle. With the animal's head under control, the formulation should be administered about 2 cm caudal from the anterior (rostral) edge of the pinna at the base of the ear. The skin at the base of the selected ear should be pinched and the product injected into the subcutaneous tissue. Following subcutaneous administration, the needle should be withdrawn from the skin as pressure is applied with the thumb at the point of insertion for several seconds. If leakage occurs then pressure should be applied for several additional seconds.
Diagram: Ear injection procedure
Adverse reactions
Swelling and inflammation may be found at the injection site in some animals. The swelling generally disappears within 7 days of treatment and generally resolves without any medical treatment.
In rare cases, adverse reactions such as transitory salivation, depression, drowsiness and ataxia might occur. No particular treatment is required; these symptoms usually disappear within 24 to 48 hours. There is no specific antidote.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
